Investment
Features
FeesSafety
Academy
More
Pluang+

Rome Protocol's Hadrian testnet enables MetaMask and Phantom users to share a Solana-based lending pool.

Protocol Fundamentals
19 Oct 2026
Tokenpost
View Source
Bullish
Rome Protocol's Hadrian testnet enables MetaMask and Phantom users to share a Solana-based lending pool.

Rome Protocol has launched the Hadrian testnet, allowing MetaMask and Phantom wallet users to access a shared Compound v3 lending pool on Solana Devnet. This testnet executes Ethereum Virtual Machine (EVM) code within Solana, enabling developers to test decentralized finance (DeFi) lending functions across Ethereum and Solana wallets. Users can supply collateral, borrow, repay, and withdraw USDC using test tokens with no real-world value. Hadrian also supports Solidity contracts calling native Solana programs, offering developers a platform to explore cross-chain DeFi application performance before mainnet deployment.

The launch of Rome's Hadrian testnet enabling Ethereum and Solana wallets to share a lending pool is presented here with Pluang's market snapshot as of Oct 20, 2026 04:42 WIB: Among 50 major cryptocurrencies, 46 rose and 3 fell today. Polkadot (DOT) gained 7.63% to Rp20.410 but saw predominantly sell orders (83% Sell / 17% Buy) and a typical hold time of 121 days. In contrast, Cosmos (ATOM) rose 7.33% to Rp31.274 with a strong buy order activity (24% Sell / 76% Buy) and a shorter hold time of 61 days. MultiversX (EGLD) increased 6.13% to Rp64.853, balancing sell and buy orders more evenly (43% Sell / 57% Buy) and a hold time of 86 days.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
1 hour ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
1 hour ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
2 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
3 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App